3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
27
Phase 1
17
Phase 1/2
14
Phase NA
11
Phase 3
9
Phase 4
3
Phase EARLY_PHASE1
2
Phase 2/3
2
Status
Completed
4
Recruiting
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Neoplasms
23
Carcinoma, Non-Small-Cell Lung
15
Prostatic Neoplasms
14
Stomach Neoplasms
12
Colorectal Neoplasms
12
Breast Neoplasms
12
Pancreatic Neoplasms
10
Leukemia, Myeloid, Acute
10
Neoplasm Metastasis
9
Lung Neoplasms
9
Hematologic Neoplasms
9
Head and Neck Neoplasms
9
Carcinoma, Hepatocellular
9
Squamous Cell Carcinoma of Head and Neck
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Ovarian Neoplasms
8
Endometrial Neoplasms
8
Myasthenia Gravis
7
Melanoma
7
Uterine Cervical Neoplasms
6
Recurrence
6
Rectal Neoplasms
6
Neoplasms by Site
6
Neoplasms by Histologic Type
6
Lymphoma
6
Leukemia
6
Urinary Bladder Neoplasms
5
Neoplasms, Plasma Cell
5
Infections
5
Colonic Neoplasms
5
Interventions
Somatostatin
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Neuroendocrine Tumors
×
Clear all
NCT06943755
2026-04-17
STELLAR-311
Exelixis
Phase 2/3
Recruiting
440 enrolled
NCT06855095
2025-03-03
ATSA
The Netherlands Cancer Institute
Phase 2/3
Recruiting
39 enrolled